Dual Pathway Inhibition in Patients With mRCC: A Case Series From Kuwait Highlighting the Role of Avelumab and Axitinib
Abstract
Background Renal cell carcinoma (RCC) accounts for approximately 3% of adult cancers and is characterized by aggressive behavior and early metastatic potential. The therapeutic paradigm of metastatic RCC (mRCC) has evolved from tyrosine kinase inhibitors (TKIs) alone to immune checkpoint inhibitors (ICIs) and ICI–TKI combinations. Avelumab, an anti–PD‐L1 antibody, in combination with axitinib, a VEGFR‐targeted TKI, has demonstrated efficacy in pivotal trials such as JAVELIN Renal 101. Objective The objective of this study is to report the clinical outcomes of four patients with advanced mRCC and extensive metastases treated with avelumab with axitinib at the Kuwait Cancer Control Center (KCCC). Methods This case series describes diagnostic imaging, treatment regimens, and disease progression in four patients. Imaging modalities included PET‐CT and CT scans, performed at multiple intervals to assess therapeutic response, disease control, and treatment tolerability. Results All patients demonstrated favorable radiological and clinical responses despite high metastatic burden and the presence of comorbidities, including disease regression or stable disease across multiple metastatic sites. Treatment was generally well tolerated, with no Grade III or IV toxicities recorded. Conclusion This case series involving patients treated at KCCC demonstrates the real‐world efficacy and tolerability of avelumab plus axitinib as a first‐line option for metastatic renal cell carcinoma, even…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.